Updated Data Confirm Benefit of Single SBRT Dose for NSCLC
This video examines updated data from a phase II trial that compared a single dose of high-intensity SBRT with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer.
In this video, Anurag Singh, MD, of the Roswell Park Cancer Institute, discusses updated data from a randomized phase II trial that compared a single dose of high-intensity stereotactic body radiation therapy (SBRT) with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer (NSCLC).
The study, which included 98 patients, reported a 2-year overall survival rate of 72% for patients treated with the single 30-Gy fraction compared with 59% for those who received 60 Gy over three fractions. The frequency of grade 3 or higher adverse events was similar between the two groups (29% in patients who received one dose vs 35%).
Singh presented the results (abstract 4) at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.
Video courtesy of Roswell Park Cancer Institute.
